Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs focuses on providing advanced immune cell therapies to target and combat malignant diseases effectively. With our expertise in CAR-T cell technology, our team of experts is committed to supporting the development of innovative immune cell therapies targeting ERBB3-expressing cancers. We offer a variety of anti-ERBB3 CAR products to meet the diverse needs of researchers in the field of cancer immunotherapy.
Human epidermal growth factor receptor 3 (ERBB3, HER3) is a receptor tyrosine kinase that plays a crucial role in cell growth, differentiation, and survival. It is a member of the ERBB family of receptor kinases, which includes EGFR (ERBB1), HER2 (ERBB2), and ERBB4. Dysregulation of ERBB3 signaling has been implicated in various cancers, including breast, ovarian, and prostate cancers, making it an attractive target for therapeutic intervention. Targeting ERBB3 with specific inhibitors, monoclonal antibodies or CAR-T therapy has shown promise in preclinical studies and clinical trials as a potential strategy for cancer therapy.
Associated Disease
Creative Biolabs offers comprehensive in vitro assays to assess the efficacy and safety of anti-ERBB3 CAR-T cell therapy, including:
We provide anti-ERBB3 CAR-T expression test services that are used to determine the expression levels of CAR targeting the ERBB3 protein on T cells. Our experts utilize several molecular techniques such as WB, FC, and PCR to measure the expression levels of the CAR construct on the T cells.
Fig.1 The anti-ERBB3 CAR expression was detected by flow cytometry and western blot.1
We utilize techniques such as cell counting, flow cytometry, and other cell proliferation assays to monitor and evaluate the proliferation of CAR-T cells. During the CAR-T proliferation test, CAR-T cells are typically cultured in vitro under controlled conditions and monitored over a specified period.
We offer comprehensive and accurate testing for evaluating the cytokine release in vitro. Our team of experts is well-equipped to deliver reliable and efficient results, ensuring the safety and efficacy of personalized cell therapy treatments.
Fig.2 The release of IL-2 and IFN-γ was detected by ELISA.1
We provide various anti-ERBB3 CAR-T cytotoxicity assays that are used to evaluate the cytotoxic activity of CAR-T cells against target cells, providing valuable information on the effectiveness of CAR-T cell therapy in killing tumor cells. Our team is dedicated to tailoring these tests to suit the specific requirements of each research project, ensuring accurate and reliable results for our clients.
Fig.3 The anti-ERBB3 CAR-T cytotoxicity against squamous cell carcinoma of the head and neck (SCCHN) tumor cells.1
Efficacy Test of Anti-ERBB3 CAR-T
We provide comprehensive in vivo assays to evaluate the efficacy of anti-ERBB3 CAR-T cells in vivo. Our experts will monitor tumor growth, assess CAR-T cell persistence, and evaluate infiltration of CAR-T cells and overall anti-tumor response using a suitable animal model such as a mouse xenograft model.
Fig.4 In vivo antitumor activity of anti-ERBB3 CAR-T against a SCCHN xenograft.1
Reference
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| CAR-YY2652 | Anti-ERBB3 (CBYY-C2439) h(41BB-CD3ζ) CAR, pCDCAR1 | CBYY-C2439 | Mouse | scfv-41BB-CD3ζ | Retroviral | T cell | |||
| CAR-YY2653 | Anti-ERBB3 (CBYY-C2440) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBYY-C2440 | Mouse | scfv-41BB-CD3ζ | Retroviral | T cell | ||
| CAR-YY3019 | Anti-ERBB3 (CBYY-C2439) h(CD28-CD3ζ) CAR, pCDCAR1 | CBYY-C2439 | Mouse | scfv-41BB-CD3ζ | Retroviral | T cell | |||
| CAR-YY3020 | Anti-ERBB3 (CBYY-C2440) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBYY-C2440 | Mouse | scfv-41BB-CD3ζ | Retroviral | T cell | ||
| CAR-WFY6697 | Anti-ERBB3 (1B4C3) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 1B4C3 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY6698 | Anti-ERBB3 (3F10F6) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 3F10F6 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY6699 | Anti-ERBB3 (DY-7G2) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | DY-7G2 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY6700 | Anti-ERBB3 (H3.90.6) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | H3.90.6 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY6701 | Anti-ERBB3 (CBFYE-0058) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYE-0058 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY6702 | Anti-ERBB3 (CBFYE-0111) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYE-0111 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY6703 | Anti-ERBB3 (CBFYE-0156) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYE-0156 | Human | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY6704 | Anti-ERBB3 (CBFYE-0161) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYE-0161 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY6705 | Anti-ERBB3 (CBFYE-0163) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYE-0163 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY6706 | Anti-ERBB3 (CBFYE-0251) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYE-0251 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY6707 | Anti-ERBB3 (CBFYE-1111) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYE-1111 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY6729 | Anti-ERBB3 (CBFYE-1133) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYE-1133 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY6730 | Anti-ERBB3 (CBFYE-1134) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYE-1134 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY6773 | Anti-ERBB3 (D22C5) h(41BB-CD3ζ) CAR, pCDCAR1 | Human, Mouse, Rat | D22C5 | Rabbit | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY6785 | Anti-ERBB3 (CBFYH-2958) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYH-2958 | Rabbit | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY6786 | Anti-ERBB3 (RTJ1) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | RTJ1 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0823-LX43 | Anti-hERBB3 (P1) ICD(CD28-OX40-CD3ζ) CAR-MA, pAd5f35 Vector | Human | P1 | Adenoviral vectors |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
